Congress Wealth Management LLC DE Boosts Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Congress Wealth Management LLC DE boosted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 114,088 shares of the medical instruments supplier's stock after acquiring an additional 4,279 shares during the quarter. Congress Wealth Management LLC DE owned about 0.51% of LeMaitre Vascular worth $10,512,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in LMAT. Raymond James Financial Inc. purchased a new position in LeMaitre Vascular during the fourth quarter valued at approximately $14,900,000. DF Dent & Co. Inc. grew its stake in shares of LeMaitre Vascular by 26.2% during the 3rd quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier's stock worth $24,037,000 after purchasing an additional 53,797 shares during the period. Barclays PLC grew its stake in shares of LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after purchasing an additional 29,180 shares during the period. State Street Corp increased its holdings in shares of LeMaitre Vascular by 3.6% during the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock valued at $76,363,000 after purchasing an additional 28,525 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in LeMaitre Vascular by 31.8% during the fourth quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier's stock valued at $9,385,000 after buying an additional 24,586 shares during the period. Hedge funds and other institutional investors own 84.64% of the company's stock.

Remove Ads

Insider Transactions at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 10.79% of the company's stock.

LeMaitre Vascular Stock Down 1.0 %

Shares of LeMaitre Vascular stock traded down $0.87 during trading hours on Friday, reaching $83.05. 194,574 shares of the company's stock were exchanged, compared to its average volume of 153,693. The business has a fifty day moving average of $93.07 and a two-hundred day moving average of $94.37. The company has a market capitalization of $1.87 billion, a P/E ratio of 45.38, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1 year low of $62.39 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts' consensus estimates of $0.49. The company had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were paid a $0.20 dividend. The ex-dividend date was Thursday, March 13th. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.96%. LeMaitre Vascular's dividend payout ratio (DPR) is 41.24%.

Wall Street Analysts Forecast Growth

LMAT has been the subject of a number of analyst reports. Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective on the stock. StockNews.com downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Finally, Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $95.25.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.